Fibrosis in Mesothelioma: Potential Role of Lysyl Oxidases

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2022 Feb 25

PMID 35205728

Authors

Lara Perryman

Steven G Gray

Affiliations

Soon will be listed here.

Abstract

Immunotherapies (such as checkpoint inhibitors) and standard chemotherapies (such as cisplatin) have limitations in the successful treatment of malignant pleural mesothelioma (MPM). Fibrosis is the accumulation of collagen in the extracellular matrix (ECM) of tissues, making them denser than that of healthy tissues and thereby affecting drug delivery and immune cell infiltration. Moreover, fibrosis severely affects the patient's breathing and quality of life. The production of collagen and its assembly is highly regulated by various enzymes such as lysyl oxidases. Many solid tumors aberrantly express the family of lysyl oxidases (LOX/LOXL). This review examines how LOX/LOXLs were found to be dysregulated in noncancerous and cancerous settings, discusses their roles in solid tumor fibrosis and pathogenesis and explores the role of fibrosis in the development and poor clinical outcomes of patients with MPM. We examine the current preclinical status of drugs targeting LOX/LOXLs and how the incorporation of such drugs may have therapeutic benefits in the treatment and management of patients with MPM.

Citing Articles

Multiple aspects of matrix stiffness in cancer progression.

Mancini A, Gentile M, Pentimalli F, Cortellino S, Grieco M, Giordano A Front Oncol. 2024; 14:1406644.

PMID: 39015505 PMC: 11249764. DOI: 10.3389/fonc.2024.1406644.

Lysyl Oxidase Family Proteins: Prospective Therapeutic Targets in Cancer.

Wang W, Wang X, Yao F, Huang C Int J Mol Sci. 2022; 23(20).

PMID: 36293126 PMC: 9602794. DOI: 10.3390/ijms232012270.

Lysyl Oxidase Family Enzymes and Their Role in Tumor Progression.

Liburkin-Dan T, Toledano S, Neufeld G Int J Mol Sci. 2022; 23(11).

PMID: 35682926 PMC: 9181702. DOI: 10.3390/ijms23116249.

References

Ikenaga N, Peng Z, Vaid K, Liu S, Yoshida S, Sverdlov D . Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal. Gut. 2017; 66(9):1697-1708. PMC: 5561383. DOI: 10.1136/gutjnl-2016-312473. View

Nicolas-Boluda A, Vaquero J, Vimeux L, Guilbert T, Barrin S, Kantari-Mimoun C . Tumor stiffening reversion through collagen crosslinking inhibition improves T cell migration and anti-PD-1 treatment. Elife. 2021; 10. PMC: 8203293. DOI: 10.7554/eLife.58688. View

Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez H, Oyasu M . Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010; 16(9):1009-17. DOI: 10.1038/nm.2208. View

Kim Y, Peyrol S, So C, Boyd C, Csiszar K . Coexpression of the lysyl oxidase-like gene (LOXL) and the gene encoding type III procollagen in induced liver fibrosis. J Cell Biochem. 1999; 72(2):181-8. DOI: 10.1002/(sici)1097-4644(19990201)72:2<181::aid-jcb3>3.0.co;2-d. View

Setargew Y, Wyllie K, Grant R, Chitty J, Cox T . Targeting Lysyl Oxidase Family Meditated Matrix Cross-Linking as an Anti-Stromal Therapy in Solid Tumours. Cancers (Basel). 2021; 13(3). PMC: 7865543. DOI: 10.3390/cancers13030491. View

Johnston K, Lopez K . Lysyl oxidase in cancer inhibition and metastasis. Cancer Lett. 2018; 417:174-181. DOI: 10.1016/j.canlet.2018.01.006. View

Moon H, Finney J, Xu L, Moore D, Welch D, Mure M . MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. J Biol Chem. 2013; 288(42):30000-30008. PMC: 3798469. DOI: 10.1074/jbc.C113.502310. View

Ma W, Li T, Wu S, Li J, Wang X, Li H . LOX and ACSL5 as potential relapse markers for pancreatic cancer patients. Cancer Biol Ther. 2019; 20(6):787-798. PMC: 6605990. DOI: 10.1080/15384047.2018.1564565. View

Jagirdar R, Papazoglou E, Pitaraki E, Kouliou O, Rouka E, Giannakou L . Cell and extracellular matrix interaction models in benign mesothelial and malignant pleural mesothelioma cells in 2D and 3D in-vitro. Clin Exp Pharmacol Physiol. 2020; 48(4):543-552. DOI: 10.1111/1440-1681.13446. View

10.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

11.

Gordon G, Rockwell G, Jensen R, Rheinwald J, Glickman J, Aronson J . Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol. 2005; 166(6):1827-40. PMC: 1363736. DOI: 10.1016/S0002-9440(10)62492-3. View

12.

Busacca S, Sheaff M, Arthur K, Gray S, OByrne K, Richard D . BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. J Pathol. 2011; 227(2):200-8. DOI: 10.1002/path.3979. View

13.

Yang A, Yan X, Fan X, Shi Y, Huang T, Li W . Hepatic stellate cells-specific LOXL1 deficiency abrogates hepatic inflammation, fibrosis, and corrects lipid metabolic abnormalities in non-obese NASH mice. Hepatol Int. 2021; 15(5):1122-1135. DOI: 10.1007/s12072-021-10210-w. View

14.

Jiang H, Torphy R, Steiger K, Hongo H, Ritchie A, Kriegsmann M . Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020; 130(9):4704-4709. PMC: 7456216. DOI: 10.1172/JCI136760. View

15.

Wilgus M, Borczuk A, Stoopler M, Ginsburg M, Gorenstein L, Sonett J . Lysyl oxidase: a lung adenocarcinoma biomarker of invasion and survival. Cancer. 2011; 117(10):2186-91. DOI: 10.1002/cncr.25768. View

16.

Forde P, Scherpereel A, Tsao A . Use of Immune Checkpoint Inhibitors in Mesothelioma. Curr Treat Options Oncol. 2019; 20(2):18. DOI: 10.1007/s11864-019-0613-x. View

17.

Zhao W, Yang A, Chen W, Wang P, Liu T, Cong M . Inhibition of lysyl oxidase-like 1 (LOXL1) expression arrests liver fibrosis progression in cirrhosis by reducing elastin crosslinking. Biochim Biophys Acta Mol Basis Dis. 2018; 1864(4 Pt A):1129-1137. DOI: 10.1016/j.bbadis.2018.01.019. View

18.

Maher B . Epidemiology: Fear in the dust. Nature. 2010; 468(7326):884-5. DOI: 10.1038/468884a. View

19.

Peacock E, Madden J . Administration of beta-aminopropionitrile to human beings with urethral strictures: A prelimary report. Am J Surg. 1978; 136(5):600-5. DOI: 10.1016/0002-9610(78)90317-3. View

20.

Cox T, Erler J . Molecular pathways: connecting fibrosis and solid tumor metastasis. Clin Cancer Res. 2014; 20(14):3637-43. DOI: 10.1158/1078-0432.CCR-13-1059. View